Drug Discovery

Drug response changes in the presence of ECM. Evaluate drug candidates in disease-relevant ECM settings IN MATRICO® that yield more predictive, in vivo-like results.

Liver ECM

MTHNLV201	Human Normal NativeCoat™ Liver ECM Coating
MTHDLV201	Human Diseased NativeCoat™ Liver ECM Coating
MTHNLV300	Human Normal TissueSpec® Liver ECM Scaffold (custom)
MTHDLV300	Human Diseased TissueSpec® Liver ECM Scaffold (custom)

Lung ECM

MTHNLG201	Human Normal NativeCoat™ Lung ECM Coating
MTHDLG201	Human Diseased NativeCoat™ Lung ECM Coating
MTHNLG300	Human Normal TissueSpec® Lung ECM Scaffold (custom)
MTHDLG300	Human Diseased TissueSpec® Lung ECM Scaffold (custom)

IN SITE™ Metastasis Kit

MTSMS101	IN SITE™ Metastasis Hydrogel Kit
MTSMS201	IN SITE™ Metastasis Surface Coating Kit

Related Resources

Application note: Accelerating anti-fibrotic drug development with human fibrotic liver ECM substrates

Application note: Accelerating anti-fibrotic drug development with human fibrotic lung ECM substrates

Application note: IN SITE™ Metastasis Kit to accelerate anticancer drug development

Fibrotic Human Lung Extracellular Matrix as a Disease-Specific Substrate for Models of Pulmonary Fibrosis

Poster: Fibrotic liver extracellular matrix substrates for 3D in-vitro models of human liver fibrosis

Poster: Fibrotic lung extracellular matrix substrates for 3D in-vitro models of human pulmonary fibrosis

Poster: TissueSpec® Bone, Liver, and Lung ECM substrates enable disease-relevant in-vitro models of pre-metastatic tissue microenvironments.

Poster: TissueSpec® ECM Hydrogels for predictive 3D models of human cancer

Webinar: Redefining cancer research with IN SITE™ Metastasis Kit

Webinar: Transforming lung fibrosis drug discovery with the IN MATRICO® Human Lung Fibrosis platform